We recently announced a multi-year limited distribution and supply agreement with ThinkSurgical to distribute an exclusive version of the only wireless handheld T Mini miniature robotic system compatible with Persona knee. Most excitingly, we expect to file Monogram's 510K application with the FDA very soon, which is significantly ahead of schedule. We now anticipate that we can launch a surgeon guided, fully autonomous version of monogram in the first half of twenty twenty seven as opposed to the original expectation of a twenty twenty eight launch. ? We truly believe that this technology will represent a dramatic leap forward for the future of orthopedic care. We will be bringing monogram to the American Association of Hip and Knee Surgeons annual meeting later this week in Dallas to obtain additional feedback on the systems workflow from surgeons, or plan to have at least 225 robotic sales specialists, also remains very much on track. Lastly, from a global standpoint, the China related headwinds will anniversary in January of 2027, giving us visibility into improved global knee performance. SET accelerated to 7.1% growth on a constant currency basis in the quarter, including mid-single digit growth in the US. We continue to see strengths across our key franchises, including foot and ankle, sports medicine, CMFT, cranial, maxillofacial, thoracic, and upper extremities, all of which grew between mid-single digits and high teens in the period. Critically, Paragon 28 cells grew over 18%, demonstrating the successful integration of the business and representing a blueprint for future acquisitions. These results were partially offset by continued pressure in trauma and restorative therapies, both of which declined in the quarter as expected. Technology and data, bone cement and surgical grew 13% on a constant currency basis in the third quarter, once again led by the strong demand for a robotic offerings, including ROSA with Optimize and T-Mini. Technology and data sales increase over 30% in the US, which validation strategy of offering a comprehensive suite of customer-centric solutions to surgeons. Turning now to our updated outlook for the remain of 2026, with three solid quarters behind and an organic constant currency growth rate of 3.5% year to date, we are once again increasing our full year outlook. We are now raising our organic constant currency sales growth guidance to a range of three percent to three and a half percent from two and a quarter to three and a quarter, and raising also our adjusted earnings per share guidance to eight dollars and fifty cents to eight dollars and sixty cents from the previous guidance of eight dollars. to $8.59. This increased outlook captures our expectations for consistent global market dynamics, ongoing risk of US Salesforce disruption, China-related headwinds to the tune of nearly 100 basis points in the fourth quarter, and roughly 50 basis points for the full year 2026, as well as continue pressuring NIS. With that, let's turn to our three strategic priorities: people and culture, operational excellence, and innovation and diversification. First, people and culture. We continue to make steady progress as we transition to a fully dedicated and specialized Salesforce in the US. We started this initiative in earnest earlier this year, and I'm happy to share that three quarters into an eighth-quarter journey, we are proceeding ahead of our expectations with over 75% ? of our US Salesforce now being fully dedicated. While we are seeing some disruption associated with this transition, particularly in our new franchise, overall it has been less disruptive than we initially anticipated. ? As part of this strategy, we continue to add sales reps across key growth franchises such as Appet Extremities, Sports Medicine, CMFT, Robotics, and Furananco. We're going to continue to invest back into the business to support a smooth transition. ? And we're going to manage this project with the rigor that it requires. One key data point that reinforces our confidence in the pace and success of this transition is the sales rep turnover rates, which remain at healthy single digit levels. Moving on to our second priority, operational excellence. Over the last several years, we have improved manufacturing efficiency through SKU rationalization, technology advancements, and better planning. With demand continuing to grow, we are reshaping our US manufacturing network to make it more nimble and efficient. This effort includes closing select and underutilized manufacturing sites and consolidating operations into several facilities in Warsaw, Indiana, home to our global headquarters. We're also reinvesting in our Warsaw facilities, bringing in more advanced manufacturing processes. Together, these actions reflect our continued commitment to both Warsaw and US manufacturing. At the same time, we continue to consolidate our international manufacturing footprint into lower cost geographies while working with third party experts to thoughtfully implement artificial intelligence capabilities. ? All of these initiatives are designed to address and improve our operating expense cost base, which at 46% OPEX to sales leaves room for dramatic improvement. We expect these strategies will improve flexibility, help us meet growing demand more efficiently, and provide a long-term margin tailwind as the work progresses.
Passages & reports (30) 7:53 We recently announced a multi-year limited distribution and supply agreement with ThinkSur… Report 8:13 to file Monogram's 510K application with the FDA very soon, which is significantly ahead o… Report 8:33 original expectation of a twenty twenty eight launch. Report 8:37 We Report 8:37 truly believe that this technology will represent a dramatic leap forward for the future o… Report 8:57 on the systems workflow from surgeons, or plan to have at least 225 robotic sales speciali… Report 9:17 giving us visibility into improved global knee performance. SET accelerated to 7.1% growth… Report 9:37 foot and ankle, sports medicine, CMFT, cranial, maxillofacial, thoracic, and upper extremi… Report 9:57 successful integration of the business and representing a blueprint for future acquisition… Report 10:17 surgical grew 13% on a constant currency basis in the third quarter, once again led by the… Report 10:36 validation strategy of offering a comprehensive suite of customer-centric solutions to sur… Report 10:56 of 3.5% year to date, we are once again increasing our full year outlook. We are now raisi… Report 11:16 and raising also our adjusted earnings per share guidance to eight dollars and fifty cents… Report 11:36 outlook captures our expectations for consistent global market dynamics, ongoing risk of U… Report 11:56 for the full year 2026, as well as continue pressuring NIS. With that, let's turn to our t… Report 12:16 continue to make steady progress as we transition to a fully dedicated and specialized Sal… Report 12:35 expectations with over 75% Report 12:38 of Report 12:39 our US Salesforce now being fully dedicated. While we are seeing some disruption associate… Report 12:56 As Report 12:56 part of this strategy, we continue to add sales reps across key growth franchises such as … Report 13:14 And Report 13:14 we're going to manage this project with the rigor that it requires. One key data point tha… Report 13:34 second priority, operational excellence. Over the last several years, we have improved man… Report 13:54 more nimble and efficient. This effort includes closing select and underutilized manufactu… Report 14:14 advanced manufacturing processes. Together, these actions reflect our continued commitment… Report 14:34 experts to thoughtfully implement artificial intelligence capabilities. Report 14:40 All Report 14:41 of these initiatives are designed to address and improve our operating expense cost base, … Report 15:00 efficiently, and provide a long-term margin tailwind as the work progresses. Report